What ownership stake in OVID does Affinity Asset Advisors report?

Affinity Asset Advisors and Michael Cho report beneficial ownership of 12,149,166 Ovid Therapeutics shares , including warrant shares. This position represents approximately 9.0% of Ovid’s common stock , based on the company’s disclosed shares outstanding plus the shares underlying the reported warrants.

How is Affinity Asset Advisors’ OVID position structured?

The OVID position is held directly by Affinity Healthcare Fund, LP . Affinity Asset Advisors, LLC is the fund’s investment manager, and Michael Cho is its managing member. Their 12,149,166-share stake includes 4,999,166 shares issuable upon exercise of warrants held by the fund.

What percentage of OVID’s shares does 12,149,166 represent?

Affinity and Michael Cho state their 12,149,166 shares represent about 9.0% of Ovid’s common stock . This percentage is calculated using 130,184,353 shares outstanding as of December 15, 2025, plus 4,999,166 shares issuable upon exercise of the reported warrants.

Does Affinity intend to influence control of Ovid Therapeutics (OVID)?

The filers certify the OVID securities were acquired and are held in the ordinary course of business . They state the holdings were not acquired and are not held for the purpose or effect of changing or influencing control of Ovid Therapeutics.

Who are the reporting persons in this OVID Schedule 13G/A filing?

The reporting persons are Affinity Asset Advisors, LLC , a Delaware investment adviser, and Michael Cho , a U.S. individual. Affinity is investment manager to Affinity Healthcare Fund, LP, and Cho is Affinity’s managing member, leading to shared beneficial ownership reporting for the OVID stake.

How much of Affinity’s OVID position comes from warrants?

Out of the reported 12,149,166 beneficially owned OVID shares , 4,999,166 shares are issuable upon exercise of warrants held by the fund. The remainder consists of already outstanding common shares, all of which are included in the 9.0% beneficial ownership calculation.

Ovid Therapeutics (NASDAQ: OVID) holder reports 9% equity stake

SCHEDULE 13G

CUSIP No.

690469101

1

Names of Reporting Persons

Affinity Asset Advisors, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,149,166.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,149,166.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,149,166.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No.

690469101

1

Names of Reporting Persons

Michael Cho

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 12,149,166.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 12,149,166.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,149,166.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9 %

12

Type of Reporting Person (See Instructions)

IN, HC

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Ovid Therapeutics Inc.

(b)

Address of issuer's principal executive offices:

441 Ninth Avenue, 14th Floor, New York, New York, 10001

Item 2.

(a)

Name of person filing:

Affinity Asset Advisors, LLC Michael Cho

(b)

Address or principal business office or, if none, residence:

450 Park Avenue Suite 1403 New York, NY 10022

(c)

Citizenship:

Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States.

(d)

Title of class of securities:

Common Stock, par value $0.001 per share

(e)

CUSIP No.:

690469101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held directly by the Fund. As of the date hereof, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 12,149,166 shares of common stock, $0.001 par value per share ("Common Stock"), of Ovid Therapeutics Inc. (the "Issuer"), which amount includes 4,999,166 shares of Common Stock issuable upon the exercise of warrants to purchase shares of Common Stock ("Warrants") held directly by the Fund.

(b)

Percent of class:

As of the date hereof, the Reporting Persons beneficially own approximately 9.0% of the Common Stock outstanding. The percentage disclosed above is based on 130,184,353 shares of Common Stock of the Issuer outstanding as of December 15, 2025, as set forth in the Issuer's Prospectus filed with the Securities and Exchange Commission on December 22, 2025, plus 4,999,166 shares of Common Stock issuable upon the exercise of Warrants held by the Fund.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

As of the date hereof, the Reporting Persons have sole power to vote or to direct the vote of 12,149,166 shares of Common Stock, which amount includes 4,999,166 shares of Common Stock issuable upon the exercise of Warrants.

(ii) Shared power to vote or to direct the vote:

As of the date hereof, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock.

(iii) Sole power to dispose or to direct the disposition of:

As of the date hereof, the Reporting Persons have sole power to dispose or to direct the disposition of 12,149,166 shares of Common Stock, which amount includes 4,999,166 shares of Common Stock issuable upon the exercise of Warrants.

(iv) Shared power to dispose or to direct the disposition of:

As of the date hereof, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock.

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Affinity Asset Advisors, LLC

Signature:	/s/ Andrew Weinstein
Name/Title:	Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Date:	01/29/2026

Michael Cho

Signature:	/s/ Michael Cho
Name/Title:	Michael Cho, Self
Date:	01/29/2026

Ovid Therapeutics (NASDAQ: OVID) holder reports 9% equity stake

Rhea-AI Filing Summary

Positive

Negative

FAQ

What ownership stake in OVID does Affinity Asset Advisors report?

How is Affinity Asset Advisors’ OVID position structured?

What percentage of OVID’s shares does 12,149,166 represent?

Does Affinity intend to influence control of Ovid Therapeutics (OVID)?

Who are the reporting persons in this OVID Schedule 13G/A filing?

How much of Affinity’s OVID position comes from warrants?